86.66
-0.90 (-1.03%)
| 前收盘价格 | 87.56 |
| 成交量 | 689,498 |
| 预期市盈率 (P/E Forward) | 37.45 |
| 价格/销量 (P/S) | 5.03 |
| 股市价格/股市净资产 (P/B) | 5.86 |
| 52周波幅 |
| 营业毛利率 | 10.03% |
| 营业利益率 (TTM) | 19.12% |
| 稀释每股收益 (EPS TTM) | 1.42 |
| 季度收入增长率 (YOY) | 48.20% |
| 季度盈利增长率 (YOY) | 110.60% |
| 总债务/股东权益 (D/E MRQ) | 194.67% |
| 流动比率 (MRQ) | 9.10 |
| 营业现金流 (OCF TTM) | 49.38 M |
| 杠杆自由现金流 (LFCF TTM) | -84.81 M |
| 资产报酬率 (ROA TTM) | 4.21% |
| 股东权益报酬率 (ROE TTM) | 22.99% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | TransMedics Group, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | 1.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.70 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.03% |
| 机构持股比例 | 121.56% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| WEILL DAVID | 82.18 | - | 1,336 | 109,792 |
| 累积净数量 | 1,336 | |||
| 累积净值 ($) | 109,792 | |||
| 累积平均购买 ($) | 82.18 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| WEILL DAVID | 董事 | 11 Sep 2026 | 买 (+) | 1,336 | 82.18 | 109,792 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合